View abstract

This abstract is assigned to sessions

Presentation type	E-poster
Title	Photographical overview of successful treatment of a basocellular carcinoma with vismodegib, a selective Hedgehog pathway inhibitor

Purpose	We present a photographical overview of successful treatment of a basocellular carcinoma (BCC) of the left lower eyelid with Erivedge® (vismodegib).
Methods	One patient with a BCC of the left lower eyelid was treated with Erivedge® during 8 months.
Results	A 54-year-old woman presented with an extensive basal cell carcinoma of the left lower eyelid with infiltration into the inferior orbit. The diagnosis of a BCC was confirmed on biopsy. MRI of the orbit shows deep extension of the lesion into the orbit with enhancement of contrast including the insertion of the inferior oblique muscle and the inferior rectus muscle. Given the location and extent of the lesion, radical surgery and radiotherapy are not the first choice. Erivedge® is the first Hedgehog signaling pathway targeting agent to gain U.S. Food and Drug Administration approval in 2012. Erivedge is reimbursed in Belgium if demonstrated that it is administered for the treatment of adult patients with locally advanced basal cell carcinoma for whom surgery or radiotherapy is not a suitable treatment option, or for the treatment of adult patients with symptomatic metastatic basal cell carcinoma. This patient took one 150mg capsule of Erivedge every other day for 8 months but discontinued it due to persistent diarrhea.
Conclusion	This case discusses the effect of Erivedge in a 54-year-old woman with basal cell carcinoma located at the left lower eyelid. Erivedge is a viable alternative when radical surgery or radiotherapy are not suitable options.
Conflict of interest	No

Authors 1

Last name	COOLS
Initials	A
Department	Dpt of Ophthalmology, Ghent University Hospital
City	Ghent, Belgium

Authors 2

Last name	Ninclaus
Initials	VGS
Department	Dpt of Ophthalmology, Ghent University Hospital
City	Ghent, Belgium